Pharmaceutical compositions comprising one or more steroids one or more tetrahydrofolate components and vitamin b12

• US 20050164977A1
• Filed: 11/15/2002
• Published: 07/28/2005
• Est. Priority Date: 02/21/2002
• Status: Abandoned Application

• Current Assignee: Pantarhei Bioscience B.V.
• Original Assignee: Pantarhei Bioscience B.V.
• Inventors: Coelingh Bennink, Herman Jan Tijmen
• Application Number:
  US10/505,555
• Publication Number:
  US 20050164977A1
• Time in Patent Office: Days
• US Class Current: 514/52
• CPC Class Codes: A61K 31/56 Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• CPC Class Codes: A61K 31/565 not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 15/12 for climacteric disorders
• CPC Class Codes: A61P 15/18 Feminine contraceptives
• CPC Class Codes: A61P 5/30 Oestrogens

Abstract

The present invention is concerned with a kit for use in a hormonal contraceptive method or hormone replacement therapy in mammalian females, said kit comprising at least 10 oral dosage units containing at least 1 μg of one or more steroids selected from the group consisting of estrogens and progestogens; at least 0.1 mg of one or more tetrahydrofolate components selected from the group consisting of (6S)-tetrahydrofolic acid, 5-methyl-(6S)-tetrahydrofolic acid, 5-formyl-(6S)-tetrahydrofolic acid, 10-formyl-(6R)-tetrahydrofolic acid, 5,10-methylene-(6R)-tetrahydrofolic acid, 5,10-methenyl-(6R)-tetrahydrofolic acid, 5-formimino-(6S)-tetrahydrofolic acid, pharmaceutically acceptable salts of these tetrahydrofolic acids and glutamyl derivatives of these tetrahydrofolic acids; and at least 0.1 mg vitamin B 12. Other aspects of the present invention relate to a hormonal contraceptive method and a method of hormone replacement therapy comprising the at least once daily oral administration of one or more steroid containing dosage units to a mammalian female, wherein the dosage units additionally contain at least 0.1 mg of one or more of the aforementioned tetrahydrofolate components and at least 0.1 mg vitamin B 12.

Claims

1-17. -17. (canceled)

18. A kit for use in a hormonal contraceptive method or hormone replacement therapy in mammalian females, said kit comprising at least 10 oral dosage units containing:

a) at least 1 μ

g of one or more steroids selected from the group consisting of estrogens and progestogens;

b) at least 0.1 mg of one or more tetrahydrofolate components selected from the group consisting of (6S)-tetrahydrofolic acid, 5-methyl-(6S)-tetrahydrofolic acid, 5-formyl-(6S)-tetrahydrofolic acid, 10-formyl-(6R)-tetrahydrofolic acid, 5,10-methylene-(6R)-tetrahydrofolic acid, 5,10-methenyl-(6R)-tetrahydrofolic acid, 5-formimino-(6S)-tetrahydrofolic acid, pharmaceutically acceptable salts of these tetrahydrofolic acids and glutamyl derivatives of these tetrahydrofolic acids; and

c) at least 0.1 mg vitamin B12.

19. Kit according to claim 18, comprising at least 10 dosage units containing:

a) from 2 μ

g to 30 mg of the one or more steroids;

b) from 0.2 to 15 mg of the one or more tetrahydrofolate components and

c) from 0.2 to 20 mg vitamin B12.

20. Kit according to claim 18, wherein the kit additionally comprises one or more dosage units that contain the one or more tetrahydrofolate components and vitamin B12 in the indicated amounts, but that do not contain an estrogen or a progestogen.

21. Kit according to claim 18, wherein the one or more tetrahydrofolate components are selected from the group consisting of 5-formyl-tetrahydrofolic acid, 5-methyl-tetrahydrofolic acid, as well as pharmaceutically acceptable salts and glutamyl derivatives of these acids.

22. Kit according to claim 18, wherein the steroids are selected from the group consisting of estrogens and progestogens.

23. Kit according to claim 18, wherein the dosage units contain at least 3 mg vitamin B6.

24. A method of protecting the developing foetus in a pregnant mammalian female, said method comprising administering to the mammalian female prior to conception one or more oral dosage units containing steroids, one ore more tetrahydrofolate components and vitamin B12, wherein said dosage units contain at least 0.1 mg of one or more tetrahydrofolate components selected from the group consisting of (6S)-tetrahydrofolic acid, 5-methyl-(6S)-tetrahydrofolic acid, 5-formyl-(6S)-tetrahydrofolic acid, 10-formyl-(6R)-tetrahydrofolic acid, 5,10-methylene-(6R)-tetrahydrofolic acid, 5,10-methenyl-(6R)-tetrahydrofolic acid, 5-formimino-(6S)-tetrahydrofolic acid, pharmaceutically acceptable salts of these tetrahydrofolic acids and glutamyl derivatives of these tetrahydrofolic acids and at least 0.1 mg vitamin B12.

25. Method according to claim 24, wherein the steroids are selected from the group consisting of estrogens and progestogens.

26. Method according to claim 24, wherein the method comprises an administration regimen that provides to the female at least 18 consecutive daily dosages of:

a) from 2 μ

g to 30 mg of the one or more steroids;

b) from 0.2 to 15 mg of the one or more tetrahydrofolate components and

c) from 0.2 to 20 mg vitamin B12.

27. Method according to claim 24, wherein the one or more tetrahydrofolate components are selected from the group consisting of 5-formyl-tetrahydrofolic acid, 5-methyl-tetrahydrofolic acid, as well as pharmaceutically acceptable salts and glutamyl derivatives of these acids.

28. Method according to claim 24, wherein the method comprises the essentially continuous administration of the one or more tetrahydrofolate components and vitamin B12 during a time interval of at least 40 days.

29. Method according to claim 28, wherein the method comprises an interval of 3-8 days during which the one or more tetrahydrofolate components and vitamin B12 are administered, but during which no estrogen or progestogen is administered.

30. Method according to claim 24, wherein the one or more tetrahydrofolate components are selected from the group consisting of 5-formyl-tetrahydrofolic acid, 5-methyl-tetrahydrofolic acid, as well as pharmaceutically acceptable salts and glutamyl derivatives of these acids.

31. Method according to claim 24, wherein the dosage units contain at least 3 mg vitamin B6.

32. A method of preventing neurological symptoms associated with vitamin B12 deficiency in mammalian females using a hormonal contraceptive that has been reinforced with folate, said method comprising administering to the mammalian female one or more oral dosage units containing steroids, one ore more tetrahydrofolate components and vitamin B12, said steroids being provided in an effective amount to inhibit ovulation, wherein said dosage units contain at least 0.1 mg of one or more tetrahydrofolate components selected from the group consisting of (6S)-tetrahydrofolic acid, 5-methyl-(6S)-tetrahydrofolic acid, 5-formyl-(6S)-tetrahydrofolic acid, 10-formyl-(6R)-tetrahydrofolic acid, 5,10-methylene-(6R)-tetrahydrofolic acid, 5,10-methenyl-(6R)-tetrahydrofolic acid, 5-formimino-(6S)-tetrahydrofolic acid, pharmaceutically acceptable salts of these tetrahydrofolic acids and glutamyl derivatives of these tetrahydrofolic acids and at least 0.1 mg vitamin B12.

33. Method according to claim 32, wherein the neurological symptoms associated with vitamin B12 deficiency are selected from the group consisting of peripheral neuropathy, paresthesia and ataxia.

34. Method according to claim 32, wherein the steroids are selected from the group consisting of estrogens and progestogens.

35. Method according to claim 32, wherein the method comprises an administration regimen that provides to the female at least 18 consecutive daily dosages of:

a) from 2 μ

g to 30 mg of the one or more steroids;

b) from 0.2 to 15 mg of the one or more tetrahydrofolate components and

c) from 0.2 to 20 mg vitamin B12.

36. Method according to claim 32, wherein the one or more tetrahydrofolate components are selected from the group consisting of 5-formyl-tetrahydrofolic acid, 5-methyl-tetrahydrofolic acid, as well as pharmaceutically acceptable salts and glutamyl derivatives of these acids.

37. Method according to claim 32, wherein the method comprises the essentially continuous administration of the one or more tetrahydrofolate components and vitamin B12 during a time interval of at least 40 days.

38. Method according to claim 37, wherein the method comprises an interval of 3-8 days during which the one or more tetrahydrofolate components and vitamin B12 are administered, but during which no estrogen or progestogen is administered.

39. Method according to claim 32, wherein the one or more tetrahydrofolate components are selected from the group consisting of 5-formyl-tetrahydrofolic acid, 5-methyl-tetrahydrofolic acid, as well as pharmaceutically acceptable salts and glutamyl derivatives of these acids.

40. Method according to claim 32, wherein the dosage units contain at least 3 mg vitamin B6.

41. A method of preventing neurological symptoms associated with B12 deficiency in mammalian females undergoing hormonal replacement therapy, said method comprising administering to the mammalian female one or more oral dosage units containing steroids, one ore more tetrahydrofolate components and vitamin B12, said steroids being provided in an effective amount to prevent or suppress symptoms of hypogonadism, wherein said dosage units contain at least 0.1 mg of one or more tetrahydrofolate components selected from the group consisting of (6S)-tetrahydrofolic acid, 5-methyl-(6S)-tetrahydrofolic acid, 5-formyl-(6S)-tetrahydrofolic acid, 10-formyl-(6R)-tetrahydrofolic acid, 5,10-methylene-(6R)-tetrahydrofolic acid, 5,10-methenyl-(6R)-tetrahydrofolic acid, 5-formimino-(6S)-tetrahydrofolic acid, pharmaceutically acceptable salts of these tetrahydrofolic acids and glutamyl derivatives of these tetrahydrofolic acids and at least 0.1 mg vitamin B12.

42. Method according to claim 41, wherein the neurological symptoms associated with vitamin B12 deficiency are selected from the group consisting of peripheral neuropathy, paresthesia and ataxia.

43. Method according to claim 41, wherein the steroids are selected from the group consisting of estrogens and progestogens.

44. Method according to claim 41, wherein the method comprises an administration regimen that provides to the female at least 18 consecutive daily dosages of:

a) from 2 μ

g to 30 mg of the one or more steroids;

b) from 0.2 to 15 mg of the one or more tetrahydrofolate components and

c) from 0.2 to 20 mg vitamin B12.

45. Method according to claim 41, wherein the one or more tetrahydrofolate components are selected from the group consisting of 5-formyl-tetrahydrofolic acid, 5-methyl-tetrahydrofolic acid, as well as pharmaceutically acceptable salts and glutamyl derivatives of these acids.

46. Method according to claim 41, wherein the method comprises the essentially continuous administration of the one or more tetrahydrofolate components and vitamin B12 during a time interval of at least 40 days.

47. Method according to claim 46, wherein the method comprises an interval of 3-8 days during which the one or more tetrahydrofolate components and vitamin B12 are administered, but during which no estrogen or progestogen is administered.

48. Method according to claim 41, wherein the one or more tetrahydrofolate components are selected from the group consisting of 5-formyl-tetrahydrofolic acid, 5-methyl-tetrahydrofolic acid, as well as pharmaceutically acceptable salts and glutamyl derivatives of these acids.

49. Method according to claim 41, wherein the dosage units contain at least 3 mg vitamin B6.

50. A method of preventing folate deficiency in mammalian females using a hormonal contraceptive, said method comprising administering to the mammalian female one or more oral dosage units containing steroids, one ore more tetrahydrofolate components and vitamin B12, said steroids being provided in an effective amount to inhibit ovulation, wherein said dosage units contain at least 0.1 mg of one or more tetrahydrofolate components selected from the group consisting of (6S)-tetrahydrofolic acid, 5-methyl-(6S)-tetrahydrofolic acid, 5-formyl-(6S)-tetrahydrofolic acid, 10-formyl-(6R)-tetrahydrofolic acid, 5,10-methylene-(6R)-tetrahydrofolic acid, 5,10-methenyl-(6R)-tetrahydrofolic acid, 5-formimino-(6S)-tetrahydrofolic acid, pharmaceutically acceptable salts of these tetrahydrofolic acids and glutamyl derivatives of these tetrahydrofolic acids and at least 0.1 mg vitamin B12.

51. Method according to claim 50, wherein the steroids are selected from the group consisting of estrogens and progestogens.

52. Method according to claim 50, wherein the method comprises an administration regimen that provides to the female at least 18 consecutive daily dosages of:

d) from 2 μ

g to 30 mg of the one or more steroids;

e) from 0.2 to 15 mg of the one or more tetrahydrofolate components and

f) from 0.2 to 20 mg vitamin B12.

53. Method according to claim 50, wherein the one or more tetrahydrofolate components are selected from the group consisting of 5-formyl-tetrahydrofolic acid, 5-methyl-tetrahydrofolic acid, as well as pharmaceutically acceptable salts and glutamyl derivatives of these acids.

54. Method according to claim 50, wherein the method comprises the essentially continuous administration of the one or more tetrahydrofolate components and vitamin B12 during a time interval of at least 40 days.

55. Method according to claim 54, wherein the method comprises an interval of 3-8 days during which the one or more tetrahydrofolate components and vitamin B12 are administered, but during which no estrogen or progestogen is administered.

56. Method according to claim 50, wherein the one or more tetrahydrofolate components are selected from the group consisting of 5-formyl-tetrahydrofolic acid, 5-methyl-tetrahydrofolic acid, as well as pharmaceutically acceptable salts and glutamyl derivatives of these acids.

57. Method according to claim 50, wherein the dosage units contain at least 3 mg vitamin B6.

58. A method of preventing folate deficiency in mammalian females undergoing hormone replacement therapy, said method comprising administering to the mammalian female one or more oral dosage units containing steroids, one ore more tetrahydrofolate components and vitamin B12, said steroid being provided in an effective amount to prevent or suppress symptoms of hypogonadism, wherein said dosage units contain at least 0.1 mg of one or more tetrahydrofolate components selected from the group consisting of (6S)-tetrahydrofolic acid, 5-methyl-(6S)-tetrahydrofolic acid, 5-formyl-(6S)-tetrahydrofolic acid, 10-formyl-(6R)-tetrahydrofolic acid, 5,10-methylene-(6R)-tetrahydrofolic acid, 5,10-methenyl-(6R)-tetrahydrofolic acid, 5-formimino-(6S)-tetrahydrofolic acid, pharmaceutically acceptable salts of these tetrahydrofolic acids and glutamyl derivatives of these tetrahydrofolic acids and at least 0.1 mg vitamin B12.

59. Method according to claim 58, wherein the steroids are selected from the group consisting of estrogens and progestogens.

60. Method according to claim 58, wherein the method comprises an administration regimen that provides to the female at least 18 consecutive daily dosages of:

g) from 2 μ

g to 30 mg of the one or more steroids;

h) from 0.2 to 15 mg of the one or more tetrahydrofolate components and

i) from 0.2 to 20 mg vitamin B12.

61. Method according to claim 58, wherein the one or more tetrahydrofolate components are selected from the group consisting of 5-formyl-tetrahydrofolic acid, 5-methyl-tetrahydrofolic acid, as well as pharmaceutically acceptable salts and glutamyl derivatives of these acids.

62. Method according to claim 58, wherein the method comprises the essentially continuous administration of the one or more tetrahydrofolate components and vitamin B12 during a time interval of at least 40 days.

63. Method according to claim 61, wherein the method comprises an interval of 3-8 days during which the one or more tetrahydrofolate components and vitamin B12 are administered, but during which no estrogen or progestogen is administered.

64. Method according to claim 58, wherein the one or more tetrahydrofolate components are selected from the group consisting of 5-formyl-tetrahydrofolic acid, 5-methyl-tetrahydrofolic acid, as well as pharmaceutically acceptable salts and glutamyl derivatives of these acids.

65. Method according to claim 58, wherein the dosage units contain at least 3 mg vitamin